CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$275.5M, lower than 95% of all stocks globally
- PositionOperating margin is -44460.6%, lower than 95% of its Biotechnology peers (median -24.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.61BUSDvs all stocks (USD)
Revenue (TTM)
71.13MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9400xvs all stocks
52-Week Change
25.57%vs all stocks
Market Capitalization
2.61BUSDvs all stocks (USD)
Enterprise Value
2.11BUSDvs all stocks (USD)
Forward P/E
-8.65xvs Biotechnology peers
Price to Sales (TTM)
38.19xvs Biotechnology peers
Price to Book (MRQ)
4.87xvs Biotechnology peers
Enterprise to Revenue
29.66xvs Biotechnology peers
Enterprise to EBITDA
-5.21xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-30.16%vs Biotechnology peers
Return on Equity (TTM)
-65.74%vs Biotechnology peers
Revenue (TTM)
71.13MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.7360USDUpdated Aug 28, 2026Quarterly Revenue Growth
278.70%vs Biotechnology peers
Gross Profit (TTM)
-253.55MUSDvs all stocks (USD)
EBITDA (TTM)
-404.73MUSDvs all stocks (USD)
Net Income (TTM)
-334.03MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
278.67%vs Biotechnology peers
Operating Cash Flow (TTM)
-333.34MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-275.50MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
70.85MUSDFY2025 · Dec 31, 2025Operating Income
-363.39MUSDvs all stocks (USD)
Pre-tax Income
-342.60MUSDFY2025 · Dec 31, 2025Net Income
-342.60MUSDFY2025 · Dec 31, 2025EBIT
-337.65MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-337.19MUSDFY2025 · Dec 31, 2025Research & Development
338.93MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
95.31MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
27.40MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
4.95MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.32USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.32USDFY2025 · Dec 31, 2025Basic Shares Outstanding
84.80MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
84.80MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-342.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-286.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-287.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
212.38MUSDFY2025 · Dec 31, 2025Interest Paid
2.15MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-342.60MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
460.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
44.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.47MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.56MUSDFY2025 · Dec 31, 2025Capital Expenditures
-495.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-579.28MUSDFY2025 · Dec 31, 2025Sale of Investments
542.21MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-37.56MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
28.88MUSDFY2025 · Dec 31, 2025Other Financing Charges
30.88MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
411.95MUSDFY2025 · Dec 31, 2025Shares Outstanding
113.24MSharesUpdated Aug 28, 2026Float Shares
100.79MSharesUpdated Aug 28, 2026Shares Short
19.03MSharesUpdated Aug 28, 2026Short Ratio
10.19daysvs all stocks
Short % of Shares Outstanding
17.40%vs all stocks
% Held by Insiders
0.17%vs all stocks
% Held by Institutions
126.25%vs all stocks
Total Cash (MRQ)
981.53MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.66USDUpdated Aug 28, 2026Total Debt (MRQ)
244.73MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3696xvs Biotechnology peers
Current Ratio (MRQ)
16.95xvs Biotechnology peers
Book Value per Share (MRQ)
4.92USDUpdated Aug 28, 2026Total Assets
899.42MUSDvs all stocks (USD)
Total Current Assets
894.23MUSDFY2025 · Dec 31, 2025Total Liabilities
177.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
5.18MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
106.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
70.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
212.38MUSDFY2025 · Dec 31, 2025Other Short-term Investments
662.27MUSDFY2025 · Dec 31, 2025Accounts Payable
8.68MUSDFY2025 · Dec 31, 2025Short-term Debt
753.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
367.00KUSDFY2025 · Dec 31, 2025Long-term Debt
49.94MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.34MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.02MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.34BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
722.17MUSDvs all stocks (USD)
52-Week Low
13.18USDUpdated Aug 28, 202652-Week High
34.29USDUpdated Aug 28, 202652-Week Change
25.57%vs all stocks
Beta
0.9400xvs all stocks
50-Day MA
20.22USDUpdated Aug 28, 2026200-Day MA
23.97USDUpdated Aug 28, 2026Avg 10-Day Volume
1.16MSharesUpdated Aug 28, 2026Avg 30-Day Volume
1.68MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-3.40USDUpdated Aug 28, 2026Other Income / Expense
-1.66MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -44460.6%, lower than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: -444.606Industry median: -0.24Industry P5: -33.54Peers compared: 194
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.64
Altman Z-Score 6.71: safe zoneNotable
Altman Z-Score: 6.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$275.5M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -275,496,000Global P5: -207,399,197.484
Market cap is $2.61B, above the global median of $1.18BNotable
Market cap (USD): 2,614,785,568Global Median: 1,177,936,635.801
Companies that share the same coordination system — how they create, deliver, or capture value.
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Precigen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Olix Pharmaceuticals Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Red Cat Holdings, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Rigetti Computing Inc
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC